


Faropenem daloxate

Cat. No.:	HY-10004		
CAS No.:	141702-36-5		
Molecular Formula:	C ₁₇ H ₁₉ NO ₈ S		
Molecular Weight:	397		
Target:	Bacterial; Antibiotic		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (251.89 mM)
 H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		2.5189 mL	12.5945 mL	25.1889 mL
	5 mM		0.5038 mL	2.5189 mL	5.0378 mL
	10 mM		0.2519 mL	1.2594 mL	2.5189 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (6.30 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (6.30 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (6.30 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics. IC₅₀ Value: Target: Antibacterial
 Faropenem daloxate is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against *Streptococcus pneumoniae*, *Haemophilus influenzae* and other key pathogens implicated in acute bacterial rhinosinusitis. Clinical studies have demonstrated that, in the treatment of acute bacterial rhinosinusitis in adults, 7 days of treatment with faropenem medoxomil is as clinically and bacteriologically effective as 10 days of treatment with cefuroxime

axetil. One study showed faropenem medoxomil to be superior to cefuroxime axetil. Overall, the safety profile of faropenem medoxomil is similar to that of most comparators.

IC₅₀ & Target

β-lactam

REFERENCES

- [1]. Faqi AS, Lanphear C, Gill S, Colagiovanni DB. Juvenile toxicity study of faropenem medoxomil in beagle puppies. *Reprod Toxicol*. 2010 Dec;30(4):619-24. Epub 2010 Aug 11.
- [2]. Hadley JA, Tillotson GS, Tosiello R, Echols RM. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis. *Expert Rev Anti Infect Ther*. 2006 Dec;4(6):923-37.
- [3]. Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P. Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. *Eur Arch Otorhinolaryngol*. 2003 Apr;260(4):186-94. Epub 2002 Oct 11.
- [4]. Upchurch J, Rosemore M, Tosiello R, Kowalsky S, Echols R. Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. *Otolaryngol Head Neck Surg*. 2006 Oct;135(4):511-7.
- [5]. Gettig, Jacob P.; Crank, Christopher W.; Philbrik, Alexander H. Faropenem medoxomil. *Annals of Pharmacotherapy* (2008), 42(1), 80-90.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA